TY - JOUR
T1 - Destination therapy with left ventricular assist devices in non-transplant centres
T2 - The time is right
AU - Bayes-Genis, Antoni
AU - Muñoz-Guijosa, Christian
AU - Santiago-Vacas, Evelyn
AU - Montero, Santiago
AU - García-García, Cosme
AU - Codina, Pau
AU - Núñez, Julio
AU - Lupón, Josep
N1 - Funding Information:
Disclosure: AB-G was supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892), Fundació La MARATÓ de TV3 (201502, 201516), CIBER Cardiovascular (CB16/11/00403 and 16/11/00420) and AdvanceCat 2014-2020. All other authors have no conflicts of interest to declare. Received: 15 April 2019 Accepted: 2 August 2019 Citation: European Cardiology Review 2020;15:e19. DOI: https://doi.org/10.15420/ecr.2019.29.2 Correspondence: Antoni Bayes-Genis, Heart Institute, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n 08916, Barcelona, Spain. E: [email protected]
Publisher Copyright:
© RADCLIFFE CARDIOLOGY 2020
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or not suitable for transplant. A meta-analysis presenting head-to-head comparisons of cardiac transplant versus LVAD as destination therapy (LVAD-DT) found no difference in 1-year mortality rates between LVAD-DT and cardiac transplant (OR 1.49; 95% CI [0.48-4.66]; I2=82.8%). Moreover, a recent subanalysis from the Interagency Registry for Mechanically Assisted Circulatory Support found similar outcomes after LVAD-DT implantation in both transplant and non-transplant centres. The time is right for LVAD-DT in non-transplant centres, provided multidisciplinary heart failure teams and expertise are in place.
AB - For almost half a century, cardiac transplant has been the only long-term treatment for patients with end-stage heart failure. Implantable left ventricular assist devices (LVADs) have emerged as a new treatment option for advanced heart failure as destination therapy for patients either too old or not suitable for transplant. A meta-analysis presenting head-to-head comparisons of cardiac transplant versus LVAD as destination therapy (LVAD-DT) found no difference in 1-year mortality rates between LVAD-DT and cardiac transplant (OR 1.49; 95% CI [0.48-4.66]; I2=82.8%). Moreover, a recent subanalysis from the Interagency Registry for Mechanically Assisted Circulatory Support found similar outcomes after LVAD-DT implantation in both transplant and non-transplant centres. The time is right for LVAD-DT in non-transplant centres, provided multidisciplinary heart failure teams and expertise are in place.
KW - Cardiac transplant
KW - Destination therapy
KW - Left ventricular assist device
KW - Outcomes
UR - http://www.scopus.com/inward/record.url?scp=85096374822&partnerID=8YFLogxK
U2 - 10.15420/ecr.2019.29.2
DO - 10.15420/ecr.2019.29.2
M3 - Artículo de revisión
C2 - 32419850
AN - SCOPUS:85096374822
SN - 1758-3756
VL - 15
JO - European Cardiology Review
JF - European Cardiology Review
M1 - e19
ER -